Fourteen patients were uptitrated from 75 to 150 mg of alirocumab sc. Q2W at week 12 based on week 8 LDL-C being ≥70 mg/dL and continued this dose until week 22 (last injection); however ...

Safety. Both evolocumab and alirocumab have been reported to be safe and well tolerated, with no report of causing hepatic transaminase elevation or hepatotoxicity. Nonserious injection site ...

Well, we have a study in which we have lowered cholesterol in individuals already on a statin with one of these antibodies, alirocumab ... the antibody by injection every 4 weeks for 3 doses.

There are two antibodies already on the market that target PCSK9 – Amgen’s Repatha (evolocumab) and Sanofi/Regeneron’s Repatha (alirocumab) – but these require subcutaneous injection every ...

Sanofi and Regeneron have scored a major victory in their fight with Amgen in the market for cardiovascular drugs, after releasing data showing their Praluent injection reduces risk of ...

Although these cholesterol medications are some of the safest and most effective, they can come with unwanted side effects. We asked a doctor to explain.

Investigational REGN7508 (catalytic domain) and REGN9933 (A2 domain) are being evaluated for their potential to control thrombosis while minimizing bleeding risk in a variety of patient populations ...

Injection), other litigation and other proceedings and government investigations relating to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U.S.

Injection), other litigation and other proceedings and government investigations relating to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U ...